Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPC-TM-NET

Financiado

Cerrado

Targeting the tumour microenvironment to improve pancreatic cancer prognosis

Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal progn... ver más

31/07/2014

UMR

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

PHILIPPS UNIVERSITAET MARBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-07-31 No tenemos la información de la convocatoria

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

UMR

0.00€ | Lider

NATIMAB

N.D. | Participante

CONCENTRIS RESEARCH MANAGEME...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PA-CSC Molecular characterization and targeted elimination of metas... 2M€ Cerrado

RTI2018-101071-B-I00 FACTORES DE TRANSCRIPCION EN CANCER DE PANCREAS: DE LA BIOLO... 399K€ Cerrado

PID2021-124106OB-I00 TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS 508K€ Cerrado

SAF2014-59864-R UN ABORDAJE MULTIDISPLINAR PARA DESARROLLAR NUEVAS VIAS TERA... 702K€ Cerrado

PDASwITch Super enhancer modules controlling plasticity and response t... 161K€ Cerrado

PID2021-128125OB-I00 UNA APROXIMACION INTEGRATIVA HACIA LA PREVENCION DEL CANCER... 496K€ Cerrado

Líder del proyecto

PHILIPPS UNIVERSITAET MARBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The presence of the highest degree of desmoplasia among all solid tumours and the fact that chronic inflammatory pancreatic disease is associated with an increased risk for pancreatic cancer indicate, that the tumour microenvironment is of particular importance for carcinogenesis in the pancreas. The long-term objective of this proposal is to increase survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments. For this purpose the clinical observation will be reverse-translated into innovative in-vitro and mouse models closely mimicking the human disease. This will allow a profound study of the mechanistic basis of treatment failure by deciphering the complex network between components of the microenvironment and cancer cells leading to increased resistance to chemotherapy and infiltrative growth along adjacent lymphatic and neural structures as well as metastatic spread. Identification of cancer (stem) cell-autonomous as well as stromal-derived mediators of invasion and chemoresistance will lead to novel drug targets to overcome the current therapeutic dilemma. The consortium has been specifically designed to include all required levels of expertise: 1) surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe, 2) expert pancreatic pathologists, 3) basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas, 4) molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as 5) pharmaceutical industry specialised on drug development.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores